Skip to main content
    M

    MiMedx Group Inc (MDXG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.18
    -0.03 (-0.93%)

    Market Cap: $468.42M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    MiMedx Group Inc (MDXG) Earnings: Report Dates and Results

    Updated Oct 28, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    MiMedx Group (MDXG) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, MiMedx Group reported EPS of -$0.01. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    46%(17/37)
    Avg Surprise
    +3.54%

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.03
    Range-$0.03 - -$0.03
    7 analysts
    Revenue Consensus
    $67.86M
    Range$63.60M - $70.77M
    7 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.01
    Range$0.01 - $0.01
    2 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.04-75.0%
    60d ago$0.04-75.0%
    30d ago$0.04-75.0%
    7d ago$0.03-60.0%
    Current$0.01
    Revenue Consensus
    $65.47M
    Range$62.90M - $69.00M
    4 analysts

    Next Report

    MDXG has an expected report date of Feb 23, 2027.

    MDXG Earnings Call

    The latest MDXG earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, MDXG beat 17, missed 13 and matched 7. Revenue for the quarter ended Sep 30, 2026 was $62.28M, down 45.2% from $113.72M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.01N/AN/AN/AN/A-106.7%N/A0 up, 2 downOct 28, 2026$62.28M
    Jun 30, 2026-$0.05-$0.03-$0.04 - -$0.03-66.67%Miss-150.0%30 up, 2 downJul 29, 2026$64.36M
    Mar 31, 2026-$0.05-$0.04-$0.08 - $0.00-25.00%Miss-200.0%40 up, 2 downApr 29, 2026$58.99M
    Dec 31, 2025$0.14$0.09$0.09 - $0.13+50.70%Beat+100.0%41 up, 0 downFeb 25, 2026$118.09M
    Sep 30, 2025$0.15$0.08$0.07 - $0.08+87.50%Beat+114.3%20 up, 0 downOct 29, 2025$113.72M
    Jun 30, 2025$0.10$0.06$0.05 - $0.06+66.67%Beat+25.0%20 up, 2 downJul 30, 2025$98.61M
    Mar 31, 2025$0.05$0.06$0.05 - $0.06-16.67%Miss-28.6%21 up, 0 downApr 30, 2025$88.20M
    Dec 31, 2024$0.07$0.08$0.07 - $0.08-6.67%Miss-78.1%22 up, 0 downFeb 26, 2025$92.91M
    Sep 30, 2024$0.07$0.05$0.04 - $0.05+40.00%Beat+40.0%50 up, 0 downOct 30, 2024$84.06M
    Jun 30, 2024$0.08$0.08$0.05 - $0.100.00%In lineN/A71 up, 0 downJul 31, 2024$87.21M
    Mar 31, 2024$0.07$0.04$0.03 - $0.06+75.00%BeatN/A60 up, 0 downApr 30, 2024$84.71M
    Dec 31, 2023$0.32$0.07$0.06 - $0.08+357.14%BeatN/A40 up, 0 downFeb 28, 2024$86.83M
    Sep 30, 2023$0.05$0.05$0.04 - $0.050.00%In lineN/A30 up, 0 downOct 30, 2023$81.71M
    Jun 30, 2023$0.00-$0.03-$0.05 - $0.01+84.67%BeatN/A41 up, 0 downAug 1, 2023$81.26M
    Mar 31, 2023-$0.03-$0.07-$0.10 - -$0.07+57.14%BeatN/A30 up, 0 downMay 2, 2023$71.68M
    Dec 31, 2022-$0.02-$0.04-$0.09 - $0.00+50.00%Beat-300.0%30 up, 0 downFeb 28, 2023$74.38M
    Sep 30, 2022-$0.06-$0.12-$0.12 - -$0.03+50.00%BeatN/A40 up, 0 downNov 2, 2022$67.69M
    Jun 30, 2022-$0.08-$0.08-$0.08 - -$0.020.00%In lineN/A30 up, 0 downAug 2, 2022$66.88M
    Mar 31, 2022-$0.09-$0.10-$0.10 - -$0.10+10.00%BeatN/A20 up, 0 downMay 3, 2022$58.89M
    Dec 31, 2021$0.01-$0.03-$0.08 - $0.01+133.33%BeatN/A30 up, 0 downFeb 28, 2022$50.81M
    Sep 30, 2021-$0.01-$0.07-$0.12 - -$0.05+85.71%Beat-103.7%3N/ANov 2, 2021$63.07M
    Jun 30, 2021-$0.05-$0.08-$0.12 - -$0.02+37.50%Beat-171.4%3N/AAug 3, 2021$68.17M
    Mar 31, 2021-$0.09-$0.19-$0.19 - -$0.19+52.63%BeatN/A1N/AApr 28, 2021$59.97M
    Dec 31, 2020-$0.17-$0.05-$0.05 - -$0.05-240.00%Miss-144.7%1N/AMar 8, 2021$68.55M
    Sep 30, 2020$0.27N/AN/AN/AN/A+145.5%N/AN/ANov 4, 2020$64.30M
    Jun 30, 2020$0.07$0.12N/A-41.67%MissN/AN/AN/AJul 6, 2020$53.65M
    Mar 31, 2020-$0.08N/AN/AN/AN/AN/AN/AN/AJun 30, 2020$61.74M
    Dec 31, 2019$0.38$0.09N/A+322.22%BeatN/AN/AN/AMar 17, 2020$76.40M
    Sep 30, 2019$0.11$0.15N/A-26.67%MissN/AN/AN/AOct 31, 2019$88.86M
    Jun 30, 2019-$0.16$0.14N/A-214.29%Miss-1087.7%N/AN/AJul 31, 2019$67.44M
    Mar 31, 2019-$0.12$0.13N/A-192.31%Miss-233.3%N/AN/AApr 26, 2019$66.56M
    Dec 31, 2018-$0.12$0.14N/A-189.07%Miss-224.7%N/AN/AFeb 21, 2019$92.59M
    Sep 30, 2018-$0.33$0.13N/A-355.23%Miss-514.8%N/AN/AOct 25, 2018$86.96M
    Jun 30, 2018$0.02$0.11N/A-85.27%Miss-76.9%N/AN/AJul 26, 2018$95.42M
    Mar 31, 2018$0.09$0.09N/A0.00%In line+28.6%N/AN/AApr 26, 2018$84.15M
    Dec 31, 2017$0.10$0.07N/A+42.86%Beat+42.9%1N/AMar 31, 2018$87.55M
    Sep 30, 2017$0.08$0.08$0.06 - $0.110.00%In line+33.3%6N/AOct 26, 2017$84.57M
    Jun 30, 2017$0.07$0.07$0.06 - $0.080.00%In line+40.0%6N/AJul 26, 2017$76.41M
    Mar 31, 2017$0.07$0.07N/A0.00%In line+75.0%N/AN/AApr 28, 2017$72.61M
    Dec 31, 2016$0.07$0.08N/A-12.50%Miss-41.7%N/AN/AFeb 23, 2017$46.57M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.44, up 51.7% from the year before. It was $0.22 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.44+51.7%
    Dec 31, 2024$0.29-13.5%
    Dec 31, 2023$0.34N/A
    Dec 31, 2022-$0.25N/A
    Dec 31, 2021-$0.14-255.6%
    Dec 31, 2020$0.09-57.1%
    Dec 31, 2019$0.21N/A
    Dec 31, 2018-$0.35-209.5%
    Dec 31, 2017$0.32+45.5%
    Dec 31, 2016$0.22N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,000 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,0307
    2026Q2Jun 30, 20266,4538
    2025Q4Dec 31, 20255,7538
    2025Q3Sep 30, 20255,9799
    2025Q2Jun 30, 20255,3328
    2025Q1Mar 31, 20255,6249
    2024Q4Dec 31, 20245,9029
    2024Q3Sep 30, 20246,6609

    2026Q3 Earnings Call

    Opening remarks

    Matthew Notarianni Head of Investor Relations Thank you, operator, and good afternoon, everyone. We are pleased to welcome you to MiMedx's third quarter 2026 operating and financial results conference call. With me on today's call are Chief Executive Officer, Joe Capper; and Chief Financial Officer, Doug Rice. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at mimedx.com. Joe will kick us off today with a summary of our third quarter 2026 operating and financial highlights, and Doug will provide a detailed review of our results for the quarter. And then we will conclude with some additional updates before we open the line for your questions. Before we begin, I would like to remind you that our comments today will include forward-looking statements, including statements regarding future sales, operating results and cash balance growth, future margins and expenses, our product portfolios, expected market sizes for our products and expectations regarding the Sanara acquisition, including expected benefits and financial performance of the combined company. These expectations are subject to risks and uncertainties, and actual results may differ materially from those anticipated due to many factors, including competition, access to customers, the reimbursement environment and unforeseen circumstances and delays. Additional factors that could impact outcomes and our results include those described in the Risk Factors section of our annual report on Form 10-K and our quarterly report on Form 10-Q. Also, our comments today include non-GAAP financial measures, and we provide a reconciliation to the most comparable GAAP measures in our press release, which is available on our website at mimedx.com. Furthermore, all our statements are as of today, October 28, 2026, and we have no obligation to update any forward-looking statement we make. With that, I'm now pleased to turn the call over to Joe Capper. Joe?

    Joseph Capper CEO Thanks, Matt, and good afternoon, everyone. Thank you for joining us on today's call. The results and trends of the third quarter reinforce the strategic rationale for the direction we are taking the company. Our Surgical business performed well despite somewhat softer procedure volumes, a trend that has been reported across the industry, while our Wound Care business continues to work through the reset precipitated by the changes to Medicare reimbursement. Additionally, we made significant progress preparing for the acquisition and subsequent integration of Sanara MedTech. However, as previously announced, the FTC has issued a second request for information, which extends the Hart-Scott-Rodino waiting period. We will work diligently with the commission to satisfy its inquiry, and we remain fully committed to the acquisition. We believe the combination of the two companies will enhance our ability to serve the marketplace and benefit patients.

    Frequently Asked Questions About MDXG

    When is MiMedx Group's next earnings date?

    MiMedx Group's next earnings report is expected for Feb 23, 2027.

    What EPS do analysts expect from MDXG next quarter?

    The consensus EPS estimate for MiMedx Group for the quarter ending Dec 31, 2026 is -$0.03 from 7 analysts, with estimates from -$0.03 to -$0.03.

    How often does MDXG beat earnings estimates?

    MiMedx Group beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +16.23%.